ECTRIMS 2014

ECTRIMS 2014
The 2014 Joint ACTRIMS-ECTRIMS MSBoston Meeting will take place on September 10-13 in Boston, MA. The conference will include sessions that address various aspects of multiple sclerosis. Check back here for ongoing coverage, or subscribe to our e-mails for conference updates.e-mails for conference updates.
September 13, 2014
Paul Wicks, PhD, vice president of innovation at PatientsLikeMe, discussed the benefits of using technology in multiple sclerosis research by patients, providers, researchers, and other decision-makers.
September 13, 2014
Despite the benefit of having more choices than ever before to treat patients with multiple sclerosis, the abundance of options has led to more complexity, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
September 13, 2014
As a medium, the Internet neither helps nor harms in multiple sclerosis care - what matters is how clinicians and patients engage in that medium, according to Paul Wicks, PhD, vice president of innovation at PatientsLikeMe.
September 12, 2014
At this year's ECTRIMS conference in Boston, Alasdair Coles, MD, University of Cambridge, discussed alemtuzumab and its effectiveness in treating multiple sclerosis.
September 12, 2014
The second year of the extension study of Lemtrada (alemtuzumab) for multiple sclerosis reported positive interim results with 70% of patients not requiring a third course of treatment.
September 12, 2014
Although there have been significant advances in multiple sclerosis management, patient preferences need to be taken into account before choosing treatment, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
September 12, 2014
Patients with multiple sclerosis want to be actively engaged in their treatment decisions, which will help their long-term health and medication adherence, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
September 12, 2014
The treatment landscape for multiple sclerosis continues to get more complex month to month, which makes biomarker discovery increasingly important for treating the disease, said Suhayl Dhib-Jalbut, MD, professor at the Rutgers University Robert Wood Johnson Medical School, during his session at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.
September 11, 2014
Although the survival rate of natalizumab-associated progressive multifocal leukoencephalopathy (PML) is better than PML in HIV patients, long-term they may need some assistance and care, Ralf Gold, Ruhr University Bochum in Germany, said at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.
September 11, 2014
Advanced imaging techniques are becoming necessary to further understanding of the progression of multiple sclerosis, according to presenters at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts, from September 10-13.
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!